Novo Nordisk and Ascendis Pharma have agreed to ... As per the deal signed yesterday (4 November), the two Danish companies will jointly develop therapeutics for metabolic and cardiovascular ...

The company is due to release data before the end of this year from a late-stage trial of CagriSema, a two-drug combination ... coverage of Danish drugmaker Novo Nordisk and its race to increase ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range. The maker ...

Novo Nordisk remains a sell due to increased competition ... which were labeled as close to patent expiration in the 2023 20-F filing. These two drugs contributed to Novo's sales, but as can ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance. The Danish pharmaceutical giant said that its net ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations, said that its net profit in the third quarter hit 27.3 billion Danish kroner, just above an LSEG ...

LONDON, Nov 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an ...

LONDON — Sales of Novo Nordisk’s obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in line with analyst expectations.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs ...

Because Marie was a doctor, she was "not a patient." Hanne Sindbaek, a Danish journalist, has written two books about Novo Nordisk and the Kroghs. We spoke to her in a lecture theater in what was ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...